SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million.
The San Francisco-based company said it had net income of 3 cents per share. Earnings, adjusted for non-recurring costs, came to 15 cents per share.
The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.
The biopharmaceutical company posted revenue of $29.2 million in the period, which did not meet Street forecasts. Eight analysts surveyed by Zacks expected $39 million.
For the year, the company reported a loss of $119 million, or 58 cents per share. Revenue was reported as $98.4 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
